Synthetic Biologics (SYN) Stock Price, News & Analysis

Company Overview

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 57,700 shs
• Average Volume: 197,338 shs
• Market Capitalization: $16.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SYN Stock Analysis - Frequently Asked Questions

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) announced its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.10.

When did Synthetic Biologics' stock split?

Synthetic Biologics's stock reverse split before market open on Monday, July 25th 2022.The 1-10 reverse split was announced on Monday, July 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Synthetic Biologics?

Shares of SYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Synthetic Biologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Synthetic Biologics investors own include Tonix Pharmaceuticals (TNXP), Advanced Micro Devices (AMD), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Palatin Technologies (PTN) and Meta Platforms (META).

Company Calendar

• Last Earnings: 11/02/2021
• Today: 8/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NYSEAMERICAN:SYN
• CIK: 894158
• Web: www.syntheticbiologics.com
• Phone: (301) 417-4364
• Fax: 301-417-4367
• Employees: 16
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.27 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.14%
• Return on Assets: -22.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.14
• Quick Ratio: 4.14

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.95 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 15,844,000
• Free Float: 15,503,000
• Market Cap: $16.16 million
• Optionable: Not Optionable
• Beta: 1.38